Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-024342
Filing Date
2025-05-09
Accepted
2025-05-09 17:01:27
Documents
58
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cpix-20250331.htm   iXBRL 10-Q 669427
2 EX-31.1 a2025q1-exhibit311.htm EX-31.1 12671
3 EX-31.2 a2025q1-exhibit312.htm EX-31.2 12664
4 EX-32.1 a2025q1-exhibit321.htm EX-32.1 6868
  Complete submission text file 0001628280-25-024342.txt   4149527

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20250331.xsd EX-101.SCH 32918
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cpix-20250331_cal.xml EX-101.CAL 51485
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20250331_def.xml EX-101.DEF 119501
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20250331_lab.xml EX-101.LAB 443025
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20250331_pre.xml EX-101.PRE 297414
61 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20250331_htm.xml XML 398118
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33637 | Film No.: 25931453
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)